Table 1 Influence of cinacalcet treatment on serum PTH, Scl, calcium and phosphate concentrations in hemodialysed patients with secondary hyperparathyroidism
Before treatment | After 3 months of treatment | After 6 months of treatment | p for trend | p vs. baseline (with Bonferroni’s correction) | ||
|---|---|---|---|---|---|---|
3 months | 6 months | |||||
Serum PTH concentration [pg/ml] | 1138 (931–1345) | 772 (551–992) | 635 (430–839) | <0.0001 | 0.0002 | <0.0001 |
Serum calcium concentration [mmol/l] | 2.15 (2.07–2.22) | 2.11 (2.04–2.17) | 2.08 (2–2.15) | 0.15 | 0.86 | 0.45 |
Serum phosphate concentration [mmol/l] | 2.02 (1.87–2.18) | 1.97 (1.81–2.14) | 1.90 (1.74–2.05) | 0.11 | 1 | 0.33 |
Plasma sclerostin concentration patients with PTH decrease [ng/ml]; (n = 42) | 1.51 (1.19–1.84) | 1.59 (1.29–1.89) | 1.75 (1.42–2.01) | 0.01 | 0.74 | 0.03 |
Plasma sclerostin concentration patients without PTH decrease [ng/ml]; (n = 16) | 2.09 (1.32–2.85) | 2.33 (1.27–3.40) | 2.30 (1.16–3.45) | 0.34 | 0.60 | 1 |